Results 131 to 140 of about 1,268 (176)
Development and External Validation of a Multivariable Model to Predict Early Minimal Symptom Expression Response in Adult Generalized Myasthenia Gravis Patients Treated With Efgartigimod. [PDF]
CNS Neurosci TherYang Y +12 more
europepmc +1 more source
Neurology, 2019 Autoimmune myasthenia gravis (MG) is a prototypical, antibody-mediated disorder involving fluctuating ocular and generalized skeletal muscle weakness. In over 90% of patients with generalized MG, serum antibodies develop against one of 3 endplate proteins (acetylcholine receptor [AChR], muscle-specific tyrosine kinase [MuSK], and lipoprotein receptor ...
Amanda C, Guidon, Vern C, Juel
openaire +3 more sources
Abdeg technology for the treatment of myasthenia gravis: efgartigimod drug experience [PDF]
Expert Review of Clinical Immunology, 2022 Myasthenia gravis is characterized by fluctuating muscle weakness that improves with rest and worsens with effort or throughout the day. Efgartigimod is a human IgG1–derived Fc fragment modified at five residues to increase its affinity for the neonatal ...
Jessica Barreto Ribeiro Dos Santos +2 more
exaly +2 more sources
Kill ‘Em All: Efgartigimod Immunotherapy for Autoimmune Diseases [PDF]
Trends in Pharmacological Sciences, 2018 Neonatal Fc receptors (FcRns) recycle IgGs by preventing their lysosome degradation. As this process also enhances half-life of pathogenic auto-IgG, inspired from the mechanisms of intravenous immunoglobulin, several inhibitors of IgG-FcRn interface have been conceived for treating autoimmune diseases.
Bayry, Jagadeesh, Kaveri, Srini
openaire +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Efficacy and safety of efgartigimod in patients with neurological autoimmune diseases
Immunology LettersMyasthenia gravis (MG) is an autoimmune disease characterized by disrupted neuromuscular synaptic transmission. Efgartigimod, a human Fc receptor antagonist, has been approved for patients with MG. Its potential use for other IgG-mediated neurological autoimmune diseases is unclear.
Huiqin Liu
exaly +3 more sources
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial [PDF]
Lancet, The, 2023 Background Primary immune thrombocytopenia is an autoimmune disorder mediated partly by platelet autoantibodies, resulting in thrombocytopenia, bleeding, and constitutional symptoms.
László Rejtő +2 more
exaly +2 more sources